Loading...
•
Dec 31, 2021
Alector Q4 2021 Earnings Report
Alector reported its Q4 and full year 2021 financial results, highlighting clinical and preclinical pipeline advancements and a strong cash position.
Key Takeaways
Alector reported Q4 2021 collaboration revenue of $14.0 million compared to $4.9 million for the same period in 2020. The company's cash, cash equivalents, and investments totaled $735.3 million as of December 31, 2021. Alector anticipates existing funds will support operations into mid-2024.
Collaboration revenue increased to $14.0 million for the quarter ended December 31, 2021, compared to $4.9 million for the same period in 2020.
Total research and development expenses were $52.8 million for the quarter ended December 31, 2021, compared to $44.4 million for the quarter ended December 31, 2020.
Net loss for the quarter ended December 31, 2021, was $55.6 million, or $0.68 per share, compared to a net loss of $52.2 million, or $0.66 per share, for the same period in 2020.
Cash, cash equivalents, and marketable securities were $735.3 million as of December 31, 2021.
Revenue by Segment
Forward Guidance
Alector anticipates that the company’s existing cash, cash equivalents, and marketable securities, including the net proceeds received from GSK in January 2022, are sufficient to fund projected operations into mid-2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...